Center on Health Equity & Access

Denise Yardley, MD, on OPTIMA, Prosigna proliferation scoring, and telling patients an endocrine strategy fits how their tumor behaves.

Agentic AI can fix behavioral health referral overload by matching patients to the right providers and boosting follow-through, cutting early dropout.

Closed-loop social care networks move beyond referrals, proving statewide scale can cut ED use and Medicaid costs while tracking real outcomes.

New cancer drugs reached patients fastest, but overall access timelines remained lengthy across the US, France, Germany, and Switzerland.

CMS value-based payment models underrepresent Black, Hispanic, dual-eligible, and disadvantaged Medicare beneficiaries compared with the broader population.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

Lack of stable reimbursement is negatively impacting clinical dermatological decisions, said Jane M. Grant-Kels, MD, FAAD.

Doug Francis of Rhythm Healthcare on what's driving respiratory and mobility care out of facilities and into patients' homes

June delivered 5 FDA firsts; FDA panel weighs peptide access; dermatology absorbs PA costs; Trump sets tariff timeline; digital QI trims LDL-C.

Clinical trial access remains the biggest barrier in sarcoma care, with travel and insurance limits keeping patients from open studies, says Vicki Keedy, MD.

June 2026 brought 5 FDA firsts across infectious disease, oncology, and rare disease, expanding treatment options and addressing unmet patient needs.

The Pharmacy Compounding Advisory Committee meets July 23-24 to discuss whether pharmacies may dispense BPC-157, TB-500, and 5 other peptides.

Dermatologists spend 13 hours weekly on prior authorization as health plans tout an 11% reduction in requests.

Trump said imported generic drugs will face no tariff for 2 years starting August 1, then a 100% rate in 2028 and 200% in 2029, extending his trade fight to the drugs most Americans actually take.

A digitally enabled quality improvement strategy lowered LDL-C and boosted treatment intensification, though most patients still missed guideline targets.

Many rural and urban areas lack preferred pharmacies. Where preferred pharmacies were available, distances were generally minimal relative to the cost savings; however, rural-urban disparities persist.

Diagnostic delays and access barriers continue to affect patients with MS, especially in under-resourced areas, World Brain Day highlights.

Reimbursement fixes, policy corrections, and expanded rural training could close dermatology's rural workforce gap, said Jane Grant-Kels, MD.

Kanita Bourne, LCSW, discusses how implicit bias, missed depression signs, and expanded doula access are shaping Black maternal health outcomes.

Global early-onset CKD mortality declined from 1990 to 2021, but incidence rose, highlighting persistent disparities and prevention needs.

Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.

Swarup Kumar, MD, also details treating incarcerated patients with bispecifics and pursuing cure-focused therapy sequencing in myeloma.

Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access.

Hospital-at-home meets inpatient safety, PBM insulin settlement lowers costs, SNAP narrows screening gaps, and execs warn innovation outpaces reimbursement.

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.